Company news

Noxopharm Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Voluntary Suspension

October 28, 2026

Trading Halt

October 26, 2026

Novel oligonucleotides data presented at Options Conference

August 31, 2026

Appendix 4E - Preliminary Financial Report

August 28, 2026

New preclinical data supports immuno-oncology approach

August 25, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 21, 2026

SOF-SKN manufacturing begins to ensure clinical trial readi

June 8, 2026

New data confirms cancer-fighting potential

May 25, 2026

Noxopharms Sofra assets to be presented at global conference

May 19, 2026

Noxopharm progresses US regulatory strategy

May 5, 2026

New data shows SOF-SKN active ingredient efficacy

April 30, 2026

Innovative collaboration further expands Sofra platform

April 26, 2026

March 2026 Quarterly Activities Report and Appendix 4C

April 23, 2026

Positive SOF-SKN dosing data shows prolonged skin retention

April 21, 2026

Noxopharm appoints Dr Olivier Laczka as new CEO

April 14, 2026

Resignation of Chief Executive Officer

April 14, 2026

Appendix 4D and FY2026 Half Year Financial Report

February 27, 2026

R&D rebate strengthens cash position

February 26, 2026

At-the-Market (ATM) agreement with Acuity Capital

February 26, 2026

Sofra breakthrough science publish in major medical journal

February 10, 2026

December 2025 Quarterly Activities Report and Appendix 4C

January 29, 2026

HERACLES clinical trial successfully completed

January 20, 2026

HERACLES clinical trial Update 5

December 2, 2025

First dose in HERACLES clinical trial Part Two

November 16, 2025

Second part of HERACLES clinical trial begins

November 4, 2025

September 2025 Quarterly Activities Report and Appendix 4C

October 29, 2025

First US patent for Sofra technology platform

October 21, 2025

Extension of Convertible Notes and Funding

September 22, 2025

HERACLES clinical trial Update 4

September 7, 2025

Appendix 4E Preliminary Final Report

August 28, 2025

HERACLES clinical trial Update 3

August 24, 2025

HERACLES clinical trial Update 2

August 10, 2025

US company demonstrates strong Sofra potential

August 4, 2025

June 2025 Quarterly Activities Report and Appendix 4C

July 29, 2025

HERACLES clinical trial - Update 1

July 28, 2025

First SOF-SKN dose in HERACLES clinical trial

July 15, 2025

Promising Sofra results from overseas company

June 11, 2025

Green light for HERACLES clinical trial

May 28, 2025

New funds from Nyrada share sales

May 19, 2025

March 2025 Quarterly Activities Report and Appendix 4C

April 29, 2025

Appendix 4D and FY2025 Half Year Financial Report

February 25, 2025

SOF-SKN passes required in vitro safety tests

February 3, 2025

December 2024 Quarterly Activities Report and Appendix 4C

January 28, 2025

Additional convertible note for long-term shareholder

November 4, 2024

September 2024 Quarterly Activities report and Appendix 4C

October 28, 2024

New funding from sophisticated investors

September 27, 2024

Advanced funding secured ahead of R&D rebate

September 5, 2024

Significant results from new brain cancer drugs

September 2, 2024

Noxopharm Targets Clinical Trial for First-in-Class Drug

August 19, 2024

Significant CRO-67 Results in Pancreatic Cancer Studies

August 14, 2024

Older news releases →

Decks

The 5 newest of 52 decks. Every deck is listed under its year.